| Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised … B Burtness, KJ Harrington, R Greil, D Soulières, M Tahara, G de Castro, ... The Lancet 394 (10212), 1915-1928, 2019 | 2271 | 2019 |
| Rituximab-related viral infections in lymphoma patients S Aksoy, H Harputluoglu, S Kilickap, DS Dede, O Dizdar, K Altundag, ... Leukemia & lymphoma 48 (7), 1307-1312, 2007 | 288 | 2007 |
| cTnT can be a useful marker for early detection of anthracycline cardiotoxicity S Kilickap, I Barista, E Akgul, K Aytemir, S Aksoyek, S Aksoy, I Celik, ... Annals of oncology 16 (5), 798-804, 2005 | 231 | 2005 |
| Targeting lysyl oxidase (LOX) overcomes chemotherapy resistance in triple negative breast cancer O Saatci, A Kaymak, U Raza, PG Ersan, O Akbulut, CE Banister, ... Nature communications 11 (1), 2416, 2020 | 203 | 2020 |
| Infectious complications of rituximab in patients with lymphoma during maintenance therapy: a systematic review and meta-analysis S Aksoy, Ö Dizdar, M Hayran, H Harputluoğlu Leukemia & lymphoma 50 (3), 357-365, 2009 | 131 | 2009 |
| Early and late arrhythmogenic effects of doxorubicin. S Kilickap, I Barista, E Akgul, K Aytemir, S Aksoy, G Tekuzman Southern medical journal 100 (3), 262-266, 2007 | 131 | 2007 |
| Cardiotoxicity of novel HER2-targeted therapies MAN Sendur, S Aksoy, K Altundag Current medical research and opinion 29 (8), 1015-1024, 2013 | 113 | 2013 |
| Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer B Boyraz, MAN Sendur, S Aksoy, T Babacan, EC Roach, ... Current medical research and opinion 29 (4), 405-414, 2013 | 111 | 2013 |
| Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE) T Bachelot, E Ciruelos, A Schneeweiss, F Puglisi, T Peretz-Yablonski, ... Annals of Oncology 30 (5), 766-773, 2019 | 107 | 2019 |
| Variation in hormone receptor and HER-2 status between primary and metastatic breast cancer: review of the literature C Arslan, E Sari, S Aksoy, K Altundag Expert opinion on therapeutic targets 15 (1), 21-30, 2011 | 97 | 2011 |
| Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre … F André, YH Park, SB Kim, T Takano, SA Im, G Borges, JP Lima, S Aksoy, ... The Lancet 401 (10390), 1773-1785, 2023 | 93 | 2023 |
| Breast cancer subtypes and outcomes of central nervous system metastases UY Arslan, B Oksuzoglu, S Aksoy, H Harputluoglu, I Turker, Y Ozisik, ... The Breast 20 (6), 562-567, 2011 | 93 | 2011 |
| Doxorubicin-induced second degree and complete atrioventricular block S Kilickap, E Akgul, S Aksoy, K Aytemir, I Barista EP Europace 7 (3), 227-230, 2005 | 93 | 2005 |
| Sonographic and electrodiagnostic evaluations in patients with aromatase inhibitor–related arthralgia O Dizdar, L Özçakar, FÜ Malas, H Harputluoglu, N Bulut, S Aksoy, ... Journal of Clinical Oncology 27 (30), 4955-4960, 2009 | 90 | 2009 |
| Outcome of non-metastatic male breast cancer: 118 patients ÜY Arslan, B Öksüzoğlu, N Özdemir, S Aksoy, N Alkış, A Gök, MA Kaplan, ... Medical Oncology 29, 554-560, 2012 | 87 | 2012 |
| A comprehensive review of denosumab for bone metastasis in patients with solid tumors G Gül, MAN Sendur, S Aksoy, AR Sever, K Altundag Current medical research and opinion 32 (1), 133-145, 2016 | 79 | 2016 |
| Demographic, clinical, and pathological characteristics of Turkish triple-negative breast cancer patients: single center experience S Aksoy, O Dizdar, H Harputluoglu, K Altundag Annals of oncology 18 (11), 1904-1906, 2007 | 74 | 2007 |
| Perspectives, knowledge, and fears of cancer patients about COVID-19 DC Guven, TK Sahin, OH Aktepe, HC Yildirim, S Aksoy, S Kilickap Frontiers in oncology 10, 1553, 2020 | 68 | 2020 |
| Accelerated hepatitis C virus replication with rituximab treatment in a non‐Hodgkin's lymphoma patient S Aksoy, H Abali, S Kilickap, M Erman, A Kars Clinical & Laboratory Haematology 28 (3), 211-214, 2006 | 68 | 2006 |
| LBA5 Primary results of the phase III KEYNOTE-412 study: Pembrolizumab (pembro) with chemoradiation therapy (CRT) vs placebo plus CRT for locally advanced (LA) head and neck … JP Machiels, Y Tao, B Burtness, M Tahara, D Rischin, GV Alves, IPF Lima, ... Annals of Oncology 33, S1399, 2022 | 66 | 2022 |
Kadri AltundagMKA Breast Cancer Clinic, Tepe PrimeVerified email at usa.net
